Related Experiment Video
Updated: Aug 15, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
[Clinical evaluation of amitryptyline hydrochloride in the treatment of depression]
Abstract:
Thirty subjects between 18 and 66 years of age with overt symptoms of depression were followed during treatment with amytryptiline. Daily dose was 75 mg in three parts for a period of three months. Thirteen subjects showed total remission from the tenth week; 15 showed significant improvement from the third week; 2 showed no change. Side effects were mild and required no medical intervention.
Related Concept Videos
Depression: Overview
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Electroconvulsive Therapy

